Statements of Changes in Equity - USD ($) |
Previously Reported [Member]
Ordinary shares [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Shares Application Money [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Reserve of Change in Value of Merger Reserves [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Reserve of change in value of foreign currency basis spreads [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Retained earnings [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Equity attributable to owners of parent [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Non-controlling interests [member]
Alps Life Science Inc [Member]
|
Previously Reported [Member]
Alps Life Science Inc [Member]
|
Ordinary shares [member] |
Ordinary shares [member]
Cilo Cybin Holdings Limited [member]
|
Retained earnings [member] |
Retained earnings [member]
Cilo Cybin Holdings Limited [member]
|
Alps Life Science Inc [Member] |
Total |
Cilo Cybin Holdings Limited [member] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning balance, value at Mar. 31, 2022 | $ 10,000 | $ 10,000 | |||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||
| Loss for the year | (552,004) | ||||||||||||||
| Other comprehensive income | |||||||||||||||
| Total comprehensive loss for the year | (552,004) | (552,004) | |||||||||||||
| Ending balance, value at Mar. 31, 2023 | $ 11,127,521 | $ 109,074 | $ (3,067,047) | $ (124,413) | $ (6,351,762) | $ 1,693,373 | $ (24,934) | $ 1,668,439 | 10,000 | (552,004) | (542,004) | ||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||
| Contributions by and distribution to owners of the Company | |||||||||||||||
| Issue of ordinary shares | 2,404,086 | (109,074) | 2,295,012 | 2,295,012 | 54,676,686 | 54,676,686 | |||||||||
| Arising from part dilution of equity interest in a subsidiary | 4,122 | 4,122 | (4,122) | ||||||||||||
| Loss for the year | (2,304,026) | (2,304,026) | (87,135) | (2,391,161) | $ (2,391,161) | 455,435 | |||||||||
| Other comprehensive income | (121,298) | (121,298) | (121,298) | (121,298) | |||||||||||
| Total comprehensive loss for the year | (121,298) | (2,304,026) | (2,425,324) | (87,135) | (2,512,459) | 455,435 | (2,512,459) | 455,435 | |||||||
| Repurchase of shares | (9,645) | (9,645) | |||||||||||||
| Share issue costs | (2,500,000) | (2,404,086) | (2,500,000) | ||||||||||||
| Ending balance, value at Mar. 31, 2024 | 13,531,607 | (3,067,047) | (245,711) | (8,651,666) | 1,567,183 | (116,191) | 1,450,992 | 52,177,041 | (96,569) | 1,450,992 | 52,080,472 | ||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||
| Issue of ordinary shares | (13,531,027) | 13,531,027 | 7,101,791 | 7,101,791 | |||||||||||
| Loss for the year | (2,513,573) | (2,513,573) | (111,165) | (2,624,738) | (585,716) | (2,624,738) | (585,716) | ||||||||
| Other comprehensive income | 57,830 | 57,830 | 57,830 | 57,830 | |||||||||||
| Total comprehensive loss for the year | 57,830 | (2,513,573) | (2,455,743) | (111,165) | (2,566,908) | (585,716) | (2,566,908) | (585,716) | |||||||
| Share issue costs | (1,261,480) | (1,261,480) | |||||||||||||
| Other comprehensive income | |||||||||||||||
| Ending balance, value at Mar. 31, 2025 | 580 | 10,463,980 | (187,881) | (11,165,239) | (888,560) | (227,356) | (1,115,916) | $ 1 | 58,017,352 | $ (18,503) | (682,285) | (1,115,916) | $ (18,502) | 57,335,067 | |
| Beginning balance, value at May. 13, 2024 | 1 | 1 | |||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||
| Loss for the year | (18,503) | (18,503) | |||||||||||||
| Ending balance, value at Mar. 31, 2025 | $ 580 | $ 10,463,980 | $ (187,881) | $ (11,165,239) | $ (888,560) | $ (227,356) | $ (1,115,916) | $ 1 | $ 58,017,352 | $ (18,503) | $ (682,285) | $ (1,115,916) | $ (18,502) | $ 57,335,067 |